– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload –
– Preclinical data demonstrate a favorable predicted therapeutic index and efficacy across multiple EpCAM-expressing tumors, including colorectal cancer (CRC) –
– CX-2051 IND filing expected by year-end 2023 –
SOUTH SAN FRANCISCO, CA, USa I October 18, 2023 I CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that the Company presented data characterizing the preclinical profile of its EpCAM-targeting ADC, CX-2051, at the World ADC conference taking place October 16-19, 2023, in San Diego, CA.
“CX-2051 is designed to address the unmet needs of patients with EpCAM-expressing tumors, including colorectal cancer, where EpCAM expression is uniformly high. EpCAM is a broadly expressed, validated anti-cancer target that to date has been limited in its development potential due to systemic, on-target off-tumor dose-limiting toxicities”, said Marcia P. Belvin, Ph.D., senior vice president and chief scientific officer at CytomX.
Continued Dr. Belvin, “Based on our experience with the Probody® Platform and our clinical experience with Probody-ADCs, we have designed CX-2051 to mask target binding in normal tissues and include a next-generation topoisomerase-1 inhibitor payload. We are encouraged by the compelling preclinical profile of CX-2051 and anticipate filing an IND for the program by the end of the year. We aim to launch Phase 1 dose escalation for CX-2051 in solid tumors in 2024, with an initial focus in metastatic colorectal cancer as a priority indication.”
Details for the presentation are as follows:
Presentation Title: Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor
“Clinical Lessons” Track
Session Date and Time: October 18, 2023, 12:30 pm PST
The full presentation is available at the following link:
Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor
Marcia P. Belvin, Ph.D., Senior Vice President, Chief Scientific Officer, CytomX Therapeutics
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics localized to the tumor microenvironment. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecific antibodies, and immune modulators such as cytokines and checkpoint inhibitors. CX-2029 is an investigational conditionally activated ADC directed toward CD71. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, and CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, partnered with Amgen. In addition, CytomX has a diverse preclinical portfolio of wholly-owned assets including CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors and CX-20511, a conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CytomX has also established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter.
SOURCE: CytomX
Post Views: 152
– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload –
– Preclinical data demonstrate a favorable predicted therapeutic index and efficacy across multiple EpCAM-expressing tumors, including colorectal cancer (CRC) –
– CX-2051 IND filing expected by year-end 2023 –
SOUTH SAN FRANCISCO, CA, USa I October 18, 2023 I CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that the Company presented data characterizing the preclinical profile of its EpCAM-targeting ADC, CX-2051, at the World ADC conference taking place October 16-19, 2023, in San Diego, CA.
“CX-2051 is designed to address the unmet needs of patients with EpCAM-expressing tumors, including colorectal cancer, where EpCAM expression is uniformly high. EpCAM is a broadly expressed, validated anti-cancer target that to date has been limited in its development potential due to systemic, on-target off-tumor dose-limiting toxicities”, said Marcia P. Belvin, Ph.D., senior vice president and chief scientific officer at CytomX.
Continued Dr. Belvin, “Based on our experience with the Probody® Platform and our clinical experience with Probody-ADCs, we have designed CX-2051 to mask target binding in normal tissues and include a next-generation topoisomerase-1 inhibitor payload. We are encouraged by the compelling preclinical profile of CX-2051 and anticipate filing an IND for the program by the end of the year. We aim to launch Phase 1 dose escalation for CX-2051 in solid tumors in 2024, with an initial focus in metastatic colorectal cancer as a priority indication.”
Details for the presentation are as follows:
Presentation Title: Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor
“Clinical Lessons” Track
Session Date and Time: October 18, 2023, 12:30 pm PST
The full presentation is available at the following link:
Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor
Marcia P. Belvin, Ph.D., Senior Vice President, Chief Scientific Officer, CytomX Therapeutics
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics localized to the tumor microenvironment. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecific antibodies, and immune modulators such as cytokines and checkpoint inhibitors. CX-2029 is an investigational conditionally activated ADC directed toward CD71. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, and CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, partnered with Amgen. In addition, CytomX has a diverse preclinical portfolio of wholly-owned assets including CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors and CX-20511, a conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CytomX has also established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter.
SOURCE: CytomX
Post Views: 152